Approaching Challenges Posed by SARS-CoV-2 Genetic Variants
Funding
Acknowledgments
Conflicts of Interest
References
- Janik, E.; Niemcewicz, M.; Podogrocki, M.; Majsterek, I.; Bijak, M. The Emerging Concern and Interest SARS-CoV-2 Variants. Pathogens 2021, 10, 633. [Google Scholar] [CrossRef]
- Dehghani, J.; Movafeghi, A.; Mathieu-Rivet, E.; Mati-Baouche, N.; Calbo, S.; Lerouge, P.; Bardor, M. Microalgae as an efficient vehicle for the production and targeted delivery of therapeutic glycoproteins against SARS-CoV-2 variants. Mar. Drugs. 2022, 20, 657. [Google Scholar] [CrossRef]
- Shang, W.; Dai, W.; Yao, C.; Xu, L.; Tao, X.; Su, H.; Li, J.; Xie, X.; Xu, Y.; Hu, M.; et al. In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. Antivir. Res. 2022, 208, 105450. [Google Scholar] [CrossRef]
- Kim, W.S.; Kim, J.H.; Lee, J.; Ka, S.Y.; Chae, H.D.; Jung, I.; Jung, S.T.; Na, J.H. Functional expression of the recombinant spike receptor binding domain of SARS-CoV-2 Omicron in the periplasm of Escherichia coli. Bioengineering 2022, 9, 670. [Google Scholar] [CrossRef]
- Hu, Q.; Zhao, Y.; Shaabani, N.; Lyu, X.; Powers, C.; Sun, H.; Cruz, V.; Stegman, K.; Xu, J.; Fossier, A.; et al. Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta variants. Mol. Ther. Nucleic Acids. 2022, 30, 465–476. [Google Scholar] [CrossRef]
- Wallace, Z.S.; Davis, J.; Niewiadomska, A.M.; Olson, R.D.; Shukla, M.; Stevens, R.; Zhang, Y.; Zmasek, C.M.; Scheuermann, R.H. Early detection of emerging SARS-CoV-2 variants of interest for experimental evaluation. Front. Bioinform. 2022, 2, 1020189. [Google Scholar] [CrossRef]
- Yang, J.; Barua, N.; Rahman, M.N.; Li, C.; Lo, N.; Yeong, K.Y.; Tsang, T.F.; Yang, X.; Cheung, Y.Y.; Tsang, A.K.L.; et al. Rapid SARS-CoV-2 Variants Enzymatic Detection (SAVED) by CRISPR-Cas12a. Microbiol. Spectr. 2022, e0326022. [Google Scholar] [CrossRef] [PubMed]
- Dacon, C.; Peng, L.; Lin, T.H.; Tucker, C.; Lee, C.D.; Cong, Y.; Wang, L.; Purser, L.; Cooper, A.J.R.; Williams, J.K.; et al. Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. Cell Host Microbe 2022, S1931-312800523-6. [Google Scholar] [CrossRef] [PubMed]
- Villar, M.; Urra, J.M.; Rodríguez-Del-Río, F.J.; Artigas-Jerónimo, S.; Jiménez-Collados, N.; Ferreras-Colino, E.; Contreras, M.; de Mera, I.G.F.; Estrada-Peña, A.; Gortázar, C.; et al. Characterization by quantitative serum proteomics of immune-related prognostic biomarkers for COVID-19 symptomatology. Front. Immunol. 2021, 12, 730710. [Google Scholar] [CrossRef]
- Pacheco-Olvera, D.L.; Saint Remy-Hernández, S.; García-Valeriano, M.G.; Rivera-Hernández, T.; López-Macías, C. Bioinformatic analysis of B- and T-cell epitopes from SARS-CoV-2 structural proteins and their potential cross-reactivity with emerging variants and other human coronaviruses. Arch. Med. Res. 2022, 53, 694–710. [Google Scholar] [CrossRef] [PubMed]
- Zali, A.; Khodadoost, M.; Gholamzadeh, S.; Janbazi, S.; Piri, H.; Taraghikhah, N.; Hannani, K.; Looha, M.A.; Mohammadi, G. Mortality among hospitalized COVID-19 patients during surges of SARS-CoV-2 alpha (B.1.1.7) and delta (B.1.617.2) variants. Sci. Rep. 2022, 12, 18918. [Google Scholar] [CrossRef]
- Woodbridge, Y.; Amit, S.; Huppert, A.; Kopelman, N.M. Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection. Nat. Commun. 2022, 13, 6706. [Google Scholar] [CrossRef]
- Magiorkinis, G. On the evolution of SARS-CoV-2 and the emergence of variants of concern. Trends Microbiol. 2022, S0966-842X(22)00291-8. [Google Scholar] [CrossRef] [PubMed]
- Safari, I.; Elahi, E. Evolution of the SARS-CoV-2 genome and emergence of variants of concern. Arch. Virol. 2022, 167, 293–305. [Google Scholar] [CrossRef] [PubMed]
- Alkhatib, M.; Svicher, V.; Salpini, R.; Ambrosio, F.A.; Bellocchi, M.C.; Carioti, L.; Piermatteo, L.; Scutari, R.; Costa, G.; Artese, A.; et al. SARS-CoV-2 variants and their relevant mutational profiles: Update summer 2021. Microbiol. Spectr. 2021, 9, e0109621. [Google Scholar] [CrossRef] [PubMed]
- Vöhringer, H.S.; Sanderson, T.; Sinnott, M.; De Maio, N.; Nguyen, T.; Goater, R.; Schwach, F.; Harrison, I.; Hellewell, J.; Ariani, C.V.; et al. COVID-19 Genomics UK (COG-UK) Consortium*, Birney, E.; Volz, E.; Funk, S.; Kwiatkowski, D.; Chand, M.; Martincorena, I.; Barrett, J.C.; Gerstung, M. Genomic reconstruction of the SARS-CoV-2 epidemic in England. Nature 2021, 600, 506–511, Erratum in Nature 2022, 606, E18. [Google Scholar] [CrossRef]
- Chavda, V.P.; Patel, A.B.; Vaghasiya, D.D. SARS-CoV-2 variants and vulnerability at the global level. J. Med. Virol. 2022, 94, 2986–3005. [Google Scholar] [CrossRef] [PubMed]
- Johnson, B.A.; Menachery, V.D. A new tool to probe SARS-CoV-2 variants. Science 2021, 374, 1557–1558. [Google Scholar] [CrossRef] [PubMed]
- Gao, F.X.; Wu, R.X.; Shen, M.Y.; Huang, J.J.; Li, T.T.; Hu, C.; Luo, F.Y.; Song, S.Y.; Mu, S.; Hao, Y.N.; et al. Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. iScience 2022, 25, 105479. [Google Scholar] [CrossRef]
- Yuan, M.; Wang, Y.; Lv, H.; Tan, T.J.C.; Wilson, I.A.; Wu, N.C. Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2. Cell Rep. 2022, 111650. [Google Scholar] [CrossRef]
- Mistry, P.; Barmania, F.; Mellet, J.; Peta, K.; Strydom, A.; Viljoen, I.M.; James, W.; Gordon, S.; Pepper, M.S. SARS-CoV-2 variants, vaccines, and host immunity. Front. Immunol. 2022, 12, 809244. [Google Scholar] [CrossRef] [PubMed]
- Singh, D.D.; Parveen, A.; Yadav, D.K. SARS-CoV-2: Emergence of new variants and effectiveness of vaccines. Front. Cell. Infect. Microbiol. 2021, 11, 777212, Erratum in Front. Cell. Infect. Microbiol. 2022, 12, 885482. [Google Scholar] [CrossRef]
- Zeng, B.; Gao, L.; Zhou, Q.; Yu, K.; Sun, F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis. BMC Med. 2022, 20, 200. [Google Scholar] [CrossRef] [PubMed]
- Huang, X.; Kon, E.; Han, X.; Zhang, X.; Kong, N.; Mitchell, M.J.; Peer, D.; Tao, W. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat. Nanotechnol. 2022, 17, 1027–1037. [Google Scholar] [CrossRef] [PubMed]
- Kingstad-Bakke, B.; Lee, W.; Chandrasekar, S.S.; Gasper, D.J.; Salas-Quinchucua, C.; Cleven, T.; Sullivan, J.A.; Talaat, A.; Osorio, J.E.; Suresh, M. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc. Natl. Acad. Sci. USA 2022, 119, e2118312119. [Google Scholar] [CrossRef]
- Sharun, K.; Dhama, K.; Pawde, A.M.; Gortázar, C.; Tiwari, R.; Bonilla-Aldana, D.K.; Rodriguez-Morales, A.J.; de la Fuente, J.; Michalak, I.; Attia, Y.A. SARS-CoV-2 in animals: Potential for unknown reservoir hosts and public health implications. Vet. Q. 2021, 41, 181–201. [Google Scholar] [CrossRef]
- Gozalo, A.S.; Clark, T.S.; Kurtz, D.M. Coronaviruses: Troubling Crown of the Animal Kingdom. Comp. Med. 2022. [Google Scholar] [CrossRef]
- Shehata, A.A.; Attia, Y.A.; Rahman, M.T.; Basiouni, S.; El-Seedi, H.R.; Azhar, E.I.; Khafaga, A.F.; Hafez, H.M. Diversity of coronaviruses with particular attention to the interspecies transmission of SARS-CoV-2. Animals 2022, 12, 378. [Google Scholar] [CrossRef]
- Maurin, M.; Fenollar, F.; Mediannikov, O.; Davoust, B.; Devaux, C.; Raoult, D. Current status of putative animal sources of SARS-CoV-2 infection in humans: Wildlife, domestic animals and pets. Microorganisms 2021, 9, 868. [Google Scholar] [CrossRef] [PubMed]
- de la Fuente, J.; Armas, O.; Barroso-Arévalo, S.; Gortázar, C.; García-Seco, T.; Buendía-Andrés, A.; Villanueva, F.; Soriano, J.A.; Mazuecos, L.; Vaz-Rodrigues, R.; et al. Good and bad get together: Inactivation of SARS-CoV-2 in particulate matter pollution from different fuels. Sci. Total Environ. 2022, 844, 157241. [Google Scholar] [CrossRef]
- Meyerowitz, E.A.; Richterman, A.; Gandhi, R.T.; Sax, P.E. Transmission of SARS-CoV-2: A review of viral, host, and environmental factors. Ann. Intern. Med. 2021, 174, 69–79. [Google Scholar] [CrossRef]
- de la Fuente, J.; Mera, I.G.F.; Gortázar, C. Challenges at the host-arthropod-coronavirus interface and COVID-19: A One Health approach. Front. Biosci. (Landmark Ed.) 2021, 26, 379–386. [Google Scholar] [CrossRef]
- Nekoei, S.; Khamesipour, F.; Benchimol, M.; Bueno-Marí, R.; Ommi, D. SARS-CoV-2 Transmission by arthropod vectors: A scoping review. Biomed. Res. Int. 2022, 2022, 4329423. [Google Scholar] [CrossRef]
- Higgs, S.; Huang, Y.S.; Hettenbach, S.M.; Vanlandingham, D.L. SARS-CoV-2 and arthropods: A review. Viruses 2022, 14, 985. [Google Scholar] [CrossRef] [PubMed]
- Löwdin, P.O. Quantum genetics and the aperiodic solid: Some aspects on the biological problems of heredity, mutations, aging, and tumors in view of the quantum theory of the DNA molecule. Adv. Quantum Chem. 1966, 2, 213–360. [Google Scholar]
- Baianu, I. Quantum genetics and quantum automata models of quantum-molecular evolution involved in the evolution of organisms and species. Nat. Prec. 2012. [Google Scholar] [CrossRef]
- Hwang, S.; Baek, S.H.; Park, D. interaction analysis of the spike protein of delta and omicron variants of SARS-CoV-2 with hACE2 and eight monoclonal antibodies using the fragment molecular orbital method. J. Chem. Inf. Model. 2022, 62, 1771–1782. [Google Scholar] [CrossRef] [PubMed]
- Genovese, L.; Zaccaria, M.; Farzan, M.; Johnson, W.; Momeni, B. Investigating the mutational landscape of the SARS-CoV-2 Omicron variant via Ab initio quantum mechanical modeling. bioRxiv 2021, 152, 1–16. [Google Scholar] [CrossRef]
- Gómez, S.A.; Rojas-Valencia, N.; Gómez, S.; Cappelli, C.; Restrepo, A. The role of spike protein mutations in the infectious power of SARS-COV-2 variants: A molecular interaction perspective. Chembiochem 2022, 23, e202100393. [Google Scholar] [CrossRef]
- de la Fuente, J.; Contreras, M. Vaccinomics: A future avenue for vaccine development against emerging pathogens. Expert Rev. Vaccines 2021, 20, 1561–1569. [Google Scholar] [CrossRef]
- Campos, D.M.O.; Silva, M.K.D.; Barbosa, E.D.; Leow, C.Y.; Fulco, U.L.; Oliveira, J.I.N. Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants. Comput. Biol. Chem. 2022, 101, 107754. [Google Scholar] [CrossRef] [PubMed]
- Galili, U. Increasing efficacy of enveloped whole-virus vaccines by in situ immune-complexing with the natural anti-gal antibody. Med. Res. Arch. 2021, 9, 2481. [Google Scholar] [CrossRef] [PubMed]
- De la Fuente, J.; Gortázar, C.; Cabezas-Cruz, A. Immunity to glycan α-Gal and possibilities for the control of COVID-19. Immunotherapy 2021, 13, 185–188. [Google Scholar] [CrossRef] [PubMed]
- Galili, U. Host synthesized carbohydrate antigens on viral glycoproteins as “Achilles’ heel” of viruses contributing to anti-viral immune protection. Int. J. Mol. Sci. 2020, 21, 6702. [Google Scholar] [CrossRef]
- Galili, U. Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes. Vaccine 2020, 38, 6487–6499. [Google Scholar] [CrossRef]
- Chen, J.M. SARS-CoV-2 replicating in nonprimate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-Gal antibodies: A minireview and proposals. J. Med. Virol. 2021, 93, 351–356. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
de la Fuente, J. Approaching Challenges Posed by SARS-CoV-2 Genetic Variants. Pathogens 2022, 11, 1407. https://doi.org/10.3390/pathogens11121407
de la Fuente J. Approaching Challenges Posed by SARS-CoV-2 Genetic Variants. Pathogens. 2022; 11(12):1407. https://doi.org/10.3390/pathogens11121407
Chicago/Turabian Stylede la Fuente, José. 2022. "Approaching Challenges Posed by SARS-CoV-2 Genetic Variants" Pathogens 11, no. 12: 1407. https://doi.org/10.3390/pathogens11121407
APA Stylede la Fuente, J. (2022). Approaching Challenges Posed by SARS-CoV-2 Genetic Variants. Pathogens, 11(12), 1407. https://doi.org/10.3390/pathogens11121407